

REVIEW – NON-*HELICOBACTER PYLORI* HELICOBACTERS

A. Ménard

INSERM, Bordeaux Research in Translational Oncology, Université de Bordeaux, Bordeaux, France

Corresponding Author: Armelle Ménard, Ph.D; email: armelle.menard@u-bordeaux.fr

Abstract: Over the past 12-months, almost 50 original publications concerning non-*Helicobacter pylori* Helicobacters were published. This review summarizes these main findings. A paragraph concerning the importance of Helicobacters in the environment is also presented. Three novel *Helicobacter* species were proposed: ‘*Helicobacter delphinicola*’ sp. nov. was isolated from the stomach of dolphins; ‘*Helicobacter monodelphidis*’ sp. nov. and ‘*Helicobacter didelphidarum*’ sp. nov. were isolated from the feces and the large intestine of opossums. Data showed the virulence of *Helicobacter suis* in mammals, supported its transmission from pigs to human, and highlighted the relevance of testing *H. suis* in gastric biopsies from patients negative for *H. pylori* infection. Data proposed longer duration treatment for successful eradication of *Helicobacter cinaedi* in humans. A role for *Helicobacter bilis* in inflammatory bowel disease and colorectal carcinogenesis was also shown in humans and new data supported the zoonotic importance of *Helicobacter* spp. in dogs. Several studies in *Helicobacter felis*-infected mice models akin to human gastric cancers have shown the importance of serine-phosphorylated-STAT3, PD-1/PD-L1 pathway and NLRC5 signaling in the promotion of gastric cancer, as well as the therapeutic potential of CCL28 blockade in gastric cancer progression. Using susceptible mice infected with enterohepatic *Helicobacter* spp. akin to human inflammatory bowel diseases, epigenetic dysregulation following chronic inflammation was shown to participate in the initiation of colorectal cancer; the protective effects of the inhibition of ALDH1A enzyme by WIN 18,446 was shown in *Smad3*^{-/-} mice; and *Helicobacter hepaticus* GroEL/Hsp60 was identified as a driver of colitis in a CD40-mediated model of colitis and its CDT promoted colitis development by activating the JAK-STAT signaling pathway. Finally, the wax moth larvae, *Galleria mellonella*, was reported to be a useful and fast model to assess virulence of enterohepatic *Helicobacter* spp.

Keywords: Animal disease, Animal models, Genomics and evolution, Human disease, Non-*helicobacter pylori*, Helicobacter, Pathogenesis.

NON-*HELICOBACTER PYLORI* HELICOBACTER (NHPP) INFECTIONS IN HUMANS

Helicobacter suis is a gastric Helicobacter naturally hosted by non-human primates and pigs and may be transmitted to humans. Although its prevalence is underestimated in humans, *H. suis* is the second most prevalent *Helicobacter* species in the human stomach where it is associated with gastric MALT lymphoma. A concomitant infection with *Helicobacter pylori* and *H. suis* lymphoma was described in a 53-year-old woman, who was diagnosed with atypical gastric mucosa-associated lymphoid tissue (MALT) lymphoma with multiple lymphomatous polypoid (MLP), most likely associated with *H. suis*¹. Eradication of *H. pylori* and *H. suis* cured the MALT lymphoma, but multiple granular elevations remained in the gastric body¹. Based on



This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/)

Koch's postulates, Rimbara et al² demonstrated the virulence of human *H. suis* isolates during infection in mice. Comparative genomics of human and porcine *H. suis* isolates revealed very similar genomes, suggesting its transmission to humans². Additionally, *H. suis* lacks orthologs of the two major virulence factors of *H. pylori*, i.e., CagA and VacA, but contains highly plastic genomic regions encoding putative strain-specific virulence factors, including type IV secretion system-associated genes.

Two Japanese studies suggested that the prevalence of NHPH may be significant and previously underestimated. A retrospective study³ showed NHPH-associated gastritis in 50 out of 3,847 Japanese patients (1.30%) over the last decade and the prevalence increased to 3.35% (30 of 896 patients) during the last 28 months. Analysis of the latter 30 positive cases identified 28 as NHPH: 26 as *H. suis* and two as *Helicobacter heilmannii*/*Helicobacter ailurogastricus*. None of these NHPH-infected patients were co-infected with *H. pylori*. Almost all NHPH-positive patients were asymptomatic but presented gastritis. This suggests that NHPH infection should be investigated in patients with gastritis whose *H. pylori*-based serology is negative³. Another study⁴ analyzed gastric biopsies obtained in 17 hospitals in Japan including 236 patients without *H. pylori* infection and who did not receive any *H. pylori*-eradication treatment. Forty-nine cases (20.8%) were positive for NHPH, of which 22 cases could not be identified, seven cases were positive for *H. heilmannii sensu stricto*/*H. ailurogastricus*, and 20 cases were positive for *H. suis*. Forty-five patients had been treated with one of the four types of triple therapy used for *H. pylori* eradication, leading to eradication of NHPH in all cases⁴. The prevalence of five NHPH was also analyzed in Iranian patients without *H. pylori* infection who were not treated with *H. pylori*-based eradication therapy. Among the 60 gastric biopsies included from dyspeptic patients, *Helicobacter salomonis*, *H. heilmannii*, *H. suis*, *Helicobacter felis* and *Helicobacter bizzozeronii* were found in 20, 13, 10, 10, 13 and 7 cases, respectively⁵. None of these NHPH were found in Iranian stray cats according to publications of this year⁶.

With regard to enterohepatic *Helicobacter* spp. (EHH), a case of *Helicobacter canis*-related bacteremia with underlying multilevel degenerative lumbar spinal stenosis was reported in a 65-year-old woman with rheumatoid arthritis treated with Tofacitinib, a Janus kinase inhibitor (JAKi), known to interfere with the host immune system⁷. The patient was in close contact with her pet dogs. This case hints at a possible zoonotic *H. canis* transmission favored by the immunosuppressive medication and highlights the increased risk of opportunistic infections with JAKi used in the treatment of rheumatoid arthritis⁷.

Helicobacter cinaedi infections are associated with a wide variety of clinical presentations ranking this *Helicobacter* species among emerging human pathogens. The number of new clinical cases involving *H. cinaedi* infection increased this year and suggests that it is an underdiagnosed cause of febrile illness⁸. *H. cinaedi*-associated refractory cellulitis was reported in 2 patients with X-linked agammaglobulinemia (XLA)⁹ and eradication required a long duration of antibiotic treatment. *H. cinaedi* co-infection with *Campylobacter* and Parainfluenza virus was diagnosed in a child with XLA and chronic abdominal pain¹⁰. Analysis of five cases of *H. cinaedi* infection revealed that the time required for a *H. cinaedi*-positive blood culture is relatively longer than that of *Campylobacter* species, especially for patients with underlying diseases, reaching up to 17 days^{11,12}. Extended treatment duration should also be considered, as a 45-day treatment was required for a patient with rhabdomyosarcoma¹². *H. cinaedi* infection also occurred in immunocompetent humans⁸. A case of *H. cinaedi* bacteremia secondary to diarrhea in an immunocompetent patient provided evidence that one route of bacteremia occurs through translocation from the intestinal tract to the bloodstream¹³. *H. cinaedi* is a fastidious, underdiagnosed pathogen whose culture from human blood samples is improved with the use of FAPlus/FNPlus bottles¹⁴.

The role of *Helicobacter bilis* was investigated in inflammatory bowel disease (IBD) (n=20), colorectal cancer (CRC) (n=58) and adenoma (AD) (n=20). Compared to normal colorectal mucosa (NC) (n=40), the study revealed a higher abundance of *H. bilis* in CRC than in IBD, AD and NC¹⁵. Similarly, the average number of CD4⁺CD45RB⁺T was also higher in CRC than in IBD and NC, with a positive correlation between the *H. bilis* abundance and density of CD4⁺CD45RB⁺T in 30 colorectal tissues. *H. bilis* detection was also associated with higher levels of IFN- γ . Taken together, these data suggest that *H. bilis* may play a role in the initiation of IBD and colitis-associated carcinogenesis, by promoting the transformation of T cells into CD4⁺CD45RB⁺T cells and increasing the expression of IFN- γ ¹⁵.

A study¹⁶ in Guatemala (n=424) revealed the lack of association between *Helicobacter* species (*H. hepaticus*, *H. bilis* and *H. pylori*) and non-alcoholic fatty liver disease and related metabolic conditions.

NON-HELICOBACTER PYLORI INFECTION IN ANIMALS

Three novel *Helicobacter* species have been proposed. '*Helicobacter delphinicola*' sp. nov. was isolated from the gastric fluid of captive common bottlenose dolphins with gastric disease¹⁷. This rod-shaped bacillus with tightly coiled spirals with two to four turns and two to six bipolar, sheathed flagella, is resistant to 2% NaCl. This species, closely related to *Helicobacter cetorum*, secretes a vacuolizing factor, like the *H. pylori* VacA toxin¹⁷. The two other proposed species were isolated from the fecal, cecal and colon contents of grey short-tailed opossums, clinically asymptomatic with and without prolapses¹⁸. '*Helicobacter monodelphidis*' sp. nov. is spiral-shaped, urease-negative and resistant to nalidixic acid, whereas '*Helicobacter didelphidarum*' sp. nov., has a fusiform morphology with periplasmic fibers, is urease-positive and susceptible to nalidixic acid. Both species appear to be closely related to *Helicobacter canadensis*¹⁸.

Whole genome sequencing of '*Helicobacter himalayensis*' isolated from the gastric mucosa of Himalayan marmots¹⁹, revealed a 1,829,936 base-pair long genome with a G+C content of 39.89%, a predicted genomic island named HhiG1, and a total of 1,769 predicted coding sequences²⁰. The genome contains 42 virulence factor genes, including those related to flagellar motility and cytolethal distending toxin (CDT). Phylogenetically, '*H. himalayensis*' clustered close to *H. cinaedi* and *H. hepaticus*²⁰.

H. suis and *H. pylori* infection were explored in a colony of symptomatic and asymptomatic rhesus macaques (n=21) used in research²¹. Nineteen macaques were positive for *H. suis* and 5 of them were also positive for *H. pylori*. Serology was an inadequate biomarker for *H. suis* diagnosis. In this study, the clinical relevance of *H. suis* remained unclear but one macaque presented a gastric ulcer strongly associated with the infection²¹. *H. pylori* and *H. suis* DNA were also detected in two free-range wild boars²².

Helicobacter species colonize healthy wild and captive marmosets and tamarins, and appear to form part of the normal microbiota. Chronic recurrent diarrhea and weight loss is a common problem in captive tamarins. Changes in the fecal microbiota of pied tamarins, a new world monkey, in a zoo in England, revealed that *Helicobacter jaachi* may be associated with chronic, recurrent diarrhea in captive callitrichids²³.

NHPH can cause disease in humans, and pets are a natural reservoir for many of these species. A rare case of hypertrophic canine gastropathy, Ménétrier-like disease, was reported in a dog with a simultaneous manifestation of granulomatous gastritis, with the presence of *Helicobacter* spp. and *Leishmania*²⁴. The dog's clinical improvement was significant after treatment for the helicobacteriosis and leishmaniasis but vomiting persisted probably due to the Ménétrier-like disease. The presence of *Helicobacter* species was also analyzed in fecal samples (n=390) from domestic dogs without gastrointestinal symptoms in Chile²⁵. These dogs commonly carry *Campylobacter* (173/390) and *Helicobacter* species (60/390) in their stools, mainly *Campylobacter upsaliensis* (169/390), *H. canis* (23/390), *Helicobacter canicola* (20/390), *H. bilis* (14/390), *Campylobacter jejuni* (8/390) and the proposed '*Helicobacter winghamensis*' species (5/390)²⁵. Another study²⁶ revealed a high prevalence (94.3%) of *Helicobacter* species in dogs (n=35) in Brazil. These *Helicobacters* were closely related to *H. heilmannii sensu stricto*, *H. salomonis*, *H. felis*, and *H. bizzozeronii*²⁶. An investigation of microbiota composition in dogs (n=33) showed that the colonic crypt of healthy dogs was mainly composed of *Helicobacter* species²⁷. These studies support the zoonotic importance of *Helicobacter* spp. in dogs.

The prevalence of *Helicobacter* species was also analyzed in the digestive tract of stray cats (n=30) in Iran. This study revealed the presence of *H. pylori* (60%), *H. canis* (43.3%) and *H. bilis* (26.7%) in their duodenum (50%), ileum (60%), colon (50%) and liver (43.3%) and a concurrent infection of the duodenum and liver was observed⁶. Antimicrobial susceptibility testing of feline *H. heilmannii* and *H. ailurogastricus* revealed that acquired resistance to azithromycin, spectinomycin, enrofloxacin, and lincomycin occasionally occurs in feline *H. heil-*

mannii isolates²⁸, suggesting that antimicrobial resistance to these antibiotics should be taken into account for human eradication treatment, as pets may constitute a reservoir for human zoonosis. Dysbiosis of fecal microbiota in cats infected with protozoal *Tritrichomonas foetus* revealed increased prevalence and abundance of *Megamonas* and *Helicobacter*²⁹.

HELICOBACTER SPP. AND THE ENVIRONMENT

Improvements in the feed efficiency of chickens should decrease production costs and reduce the demand of land area for feed production, while also reducing the environmental impact of broiler production. Metagenomics of cecal contents from chickens showed that low feed efficiency increased the abundance of *Campylobacter avium* in females and *Helicobacter pullorum* in males, suggesting that gender and food intake play a role in the colonization of chickens with these *Campylobacterales*³⁰.

Analysis of treated urban wastewater reused for irrigation in Spain³¹ provided evidence of the presence of *Helicobacter* species such as *H. pylori*, *H. hepaticus*, *H. pullorum* and *H. suis* in wastewater samples, even after disinfection treatment³¹, suggesting an increased risk for environmental safety.

MODELS FOR HELICOBACTER INFECTION

Several *H. felis* mice models akin to human gastric cancer were used. Myd88^{-/-} mice infected with *H. felis* constitute a fast-progressing gastric cancer model which allowed the early detection of tumor cells in bone marrow and peripheral blood during cancer progression³². Cytokeratins, epithelial to mesenchymal transition markers, and cancer stem cell biomarkers were pertinent and useful markers to detect aggressive forms of gastric cancers in this model³². In *H. felis*-infected Myd88^{-/-} mice, *Lactobacillus* spp. may contribute to a faster development of gastric cancer and may serve as a potential biomarker for gastric cancer³³. Another model, *H. felis*-infected mice treated with N-methyl-N-nitrosourea (MNU), was used to demonstrate an immunosuppressive role of tumor-intrinsic β -catenin signaling and the therapeutic potential of CCL28 blockade in gastric cancer progression³⁴. The effects of 5-fluorouracil and oxaliplatin were assessed in gastrin-deficient mice infected with *H. felis* and treated with MNU³⁵. These chemotherapeutic agents reduced numbers of myeloid-derived suppressor cells (MDSC) to increase the effects of anti-programmed cell death-1 (PD-1), which promotes tumor infiltration by CD8⁺ T cells³⁵. An adverse effect was the induction of PD-1 ligand (PD-L1) by tumor cells, which increases tumorigenesis and accumulation of depleted MDSC, and promotes tumor progression³⁵. PD-L1 induction should be considered in the design of therapeutic regimens. Infection of dendritic cell-depleted mice with *H. felis* showed that the PD-1/PD-L1 pathway modulates the immune function of gastric dendritic cells that protects the gastric mucosa from *Helicobacter*-induced inflammation but allows persistent *Helicobacter* colonization³⁶. In other mice models of *H. felis* infection, dendritic cell-derived TGF- β were shown to mediate the induction of mucosal regulatory T-cell response to *H. felis*, essential for the maintenance of immune tolerance in mice³⁷. In another study using *H. felis* and *H. pylori* mice models of B-cell lymphomagenesis, as well as gastric tissues from *H. pylori*-infected patients, NLRC5 (nucleotide-binding oligomerization domain-like receptors (NLR) family CARD domain-containing 5), an innate immune molecule, was shown to be a negative regulator of gastric inflammation and mucosal lymphoid formation in response to both infections. Aberrant NLRC5 signaling in macrophages can promote B-cell lymphomagenesis during chronic *Helicobacter* infection³⁸. The model of chronic *H. felis* infection in mice deficient for serine-phosphorylated-STAT3 revealed the key role of serine-phosphorylated-STAT3 in promoting *Helicobacter*-induced gastric carcinogenesis³⁹. Different genetically modified mice were infected with *H. felis* to study the regulation of Mist1-positive stem cells upon the gastric injury and inflammation induced by *H. felis*⁴⁰. Mist1 transcription factor is a marker for this corpus stem cell population that can give rise to cancer. This study showed that gastric Mist1⁺ isthmus cells are the main supplier of regenerated glands and are activated in part through the Wnt5a pathway and expand in response to injury and inflammation in mice⁴⁰.

In *H. felis*-infected mice, a vaccine with silk fibroin hydrogel as the mucosal vaccine carrier was evaluated. Data showed that gastric tissue-resident memory CD4+T (CD4+T_{RM}) cells protect against the infection, and the influence of neutrophils on gastric intraepithelial CD4+T_{RM} cell formation was shown⁴¹.

H. hepaticus infection of susceptible mice is widely used to study human IBD. Antibody therapies blocking signaling through the CD40-CD40L axis are promising treatments for IBD. The DC-LMP1/CD40-mediated colitis mouse model of spontaneous fatal colitis and dysbiosis lacks intestinal CD103+ dendritic cells and fails to induce regulatory T cells (iTreg). In these mice whose immunity is compromised, *H. hepaticus* rapidly promotes a strong intestinal inflammation and the bacterial chaperonin GroEL/Hsp60, the main specific antigen, is targeted in the absence of iTregs⁴¹. This study showed that improper immune regulation triggers IBD and colitis and highlights the importance of CD103+ DC- and iTreg-mediated immune tolerance to maintain a healthy intestinal balance during pathobiont infection⁴². Multi-omics analyses were performed to characterize IBD-induced hyperplasia/dysplasia in Rag2^{-/-}/IL10^{-/-} mice infected with *H. hepaticus*⁴³. In this model, Helicobacter-induced chronic inflammation promotes changes in methylation and hydroxymethylation patterns in the genome, altering the expression of key tumorigenesis genes and suggesting a role for epigenetic dysregulation in the initiation of colorectal cancer⁴³.

Rag2^{-/-}/IL10^{-/-} mice were co-infected with *H. pylori* and *H. hepaticus* to study IBD onset⁴⁴. Despite a similar gastric and colonic *H. pylori* colonization for both genders, only co-infected males developed more severe colitis and dysplasia, when compared to mice infected with *H. hepaticus* only. In these co-infected males, inflammatory colonic mRNA levels were upregulated. Thus, *H. pylori* and *H. hepaticus* co-infection enhances the inflammatory responses in the colon of susceptible male mice, which results in more severe colitis and dysplasia⁴⁴.

Using Smad3^{-/-} mice infected with *H. bilis*, Seamons et al⁴⁵ showed the protective effects of ALDH1A enzyme inhibition using WIN 18,446, a non-selective potent ALDH1A inhibitor known to decrease all-trans-retinoic acid levels with minimal side effects. WIN 18,446 attenuates IBD and deserves to be evaluated in other IBD models.

Dextran sodium sulfate (DSS) chemically induced colitis in mice is an IBD model. C57BL/6 mice infected with *Helicobacter muridarum* with and without DSS and indole-3-carbinol (I3C), a natural plant product⁴⁶, revealed the beneficial effect of I3C on colitis because it exerts an agonist function of the aryl hydrocarbon receptor and affects bacteria and bacterial byproducts. *H. muridarum*-infected mice are a pertinent IBD model as the immune response to *H. muridarum* mimics responses seen during DSS-chemically induced colitis and human IBD in terms of local and systemic cytokine responses and microRNA changes. Additionally, *H. muridarum* does not alter the activity of the I3C compound⁴⁶. When studying the effects of native starches on the onset of colitis in DSS-chemically induced colitis in mice, the authors showed the beneficial effects of some native starches from potato, pea, and Chinese yam, that could be used to alleviate colitis and also to inhibit *H. hepaticus*⁴⁷.

The wax moth larvae from the *Pyralidae* family, *Galleria mellonella*, was recently proposed as a model to study the virulence of different pathogens. The virulence of *H. bilis*, *H. canicola*, *H. canis*, and proposed '*H. winghamensis*' isolated from domestic dogs was assessed using the *G. mellonella* model⁴⁸. These larvae were susceptible to Helicobacter infection after four hours of infection and *H. canicola* was the highest virulent *Helicobacter* species in this model. Histopathology revealed cellular and humoral immune response, accumulation of hemocytes, nodulation, and melanin deposition in different tissues⁴⁸.

VIRULENCE FACTORS

In vitro experiments showed that soluble factors secreted by *H. felis* stimulate IL-10-producing B cells which suppress differentiation of *H. felis*-activated stimulatory dendritic cells⁴⁹.

The main virulence factor of EHHs is CDT, a genotoxin which triggers DNA breaks. The nuclear remodeling following CDT-induced DNA damage can be associated with the formation of messenger ribonucleoprotein particles concentrated and invaginated in the nuclei of giant surviving cells⁵⁰. These structures, called nucleoplasmic reticulum (NR), were observed both *in vitro* and in *H. hepaticus*-infected mice and concentrate the RNA binding proteins UNR/CSDE1

and P62/SQSTM1^{50,51}. CDT-induced NR formation is associated with cell survival and involves autophagy, which leads to selective removal of CDT-induced micronuclei-like structures and protects the cells against induced apoptotic cell death⁵¹. In another study, *IL10*^{-/-} male mice infected with *H. hepaticus* and its corresponding CDT isogenic mutant strain⁵² showed that CdtB promotes colitis development by induction of an inflammatory response and activation of the JAK-STAT signaling pathway. In this model, CDT did not affect the colonization efficiency of *H. hepaticus* and increased the NO content in the proximal colon⁵².

H. pullorum commonly colonizes the gastrointestinal tract of poultry causing gastroenteritis. It is an emerging zoonotic *Helicobacter* species that causes digestive diseases in humans through ingestion of contaminated meat. The genetic characteristics of *H. pullorum* (n=23) from different sources (poultry, meat and animals) and countries (Asian and Western countries) revealed that *H. pullorum* exhibits a high genetic diversity and two subtypes of type 6 secretion system⁵³.

Conflict of interest

The author declare that they have no conflict of interest.

REFERENCES

- Naito T, Yuge R, Tanaka S, Otani R, Kadota H, Takigawa H, Tamura T, Sentani K, Yasui W, Kitadai Y, Chayama K. Gastric mucosa-associated lymphoid tissue lymphoma in conjunction with multiple lymphomatous polyposis in the context of *Helicobacter pylori* and *Helicobacter suis* superinfection. *Clin J Gastroenterol* 2021; 14: 478-483.
- Rimbara E, Suzuki M, Matsui H, Nakamura M, Morimoto M, Sasakawa C, Masuda H, Nomura S, Osaki T, Nagata N, Shibayama K, Tokunaga K. Isolation and characterization of *Helicobacter suis* from human stomach. *Proc Natl Acad Sci U S A* 2021; 118: e2026337118.
- Tsukadaira T, Hayashi S, Ota H, Kobayashi N, Sekiguchi Y, Kodaira H, Matsumoto T, Horiuchi K, Negishi T, Kurahashi M. Prevalence, clinical features, and esophagogastroduodenoscopy (EGD) findings of non-*Helicobacter pylori* *Helicobacter* infection: a study of 50 cases at a single facility in Japan. *Helicobacter* 2021; e12811.
- Nakamura M, Ørverby A, Michimae H, Matsui H, Takahashi S, Mabe K, Shimoyama T, Sasaki M, Terao S, Kamada T, Yanaka A, Iwamoto J, Tanabe S, Tari A, Nasu S, Suzuki H, Yamagata Murayama S. PCR analysis and specific immunohistochemistry revealing a high prevalence of non-*Helicobacter pylori* *Helicobacters* in *Helicobacter pylori*-negative gastric disease patients in Japan: High susceptibility to an Hp eradication regimen. *Helicobacter* 2020; 25: e12700.
- Shafaie S, Kaboosi H, Peyravii Ghadikolaii F. Prevalence of non *Helicobacter pylori* gastric *Helicobacters* in Iranian dyspeptic patients. *BMC Gastroenterol* 2020; 20: 190.
- Elyasi B, Rezaie A, Moori Bakhtiari N, Mosallanejad B. *Helicobacter* genus in the intestine and liver of stray cats: the molecular, histopathological, and immunohistochemical study. *Braz J Microbiol* 2020; 51: 2123-2132.
- Mihevci M, Koren Krajnc M, Bombek Ihan M, Holc I. *Helicobacter canis* bacteraemia in a rheumatoid arthritis patient treated with tofacitinib: case report and literature review. *Ann Clin Microbiol Antimicrob* 2021; 20: 22.
- Fox-Lewis A, Basu I, Vesty A, Henderson G, Chhibber AV, Thomas M. *Helicobacter cinaedi* bacteremia in a returning traveler. *IDCases* 2020; 21: e00910.
- Inoue K, Sasaki S, Yasumi T, Imai K, Kusunoki T, Morio T, Kanegane H. *Helicobacter cinaedi*-Associated Refractory Cellulitis in Patients with X-Linked Agammaglobulinemia. *J Clin Immunol* 2020; 40: 1132-1137.
- Fettingner NB, Bradley JS, Ramchandrar N. An 11-year-old male with X-linked agammaglobulinemia and persistent abdominal pain. *Pediatr Infect Dis J* 2021; 40: 356-358.
- Itoh K, Iwasaki H, Shigemi H, Tsutani H, Yamauchi T. Spiral-shaped bacteremia: Difference in the duration of blood cultures between *Helicobacter* spp. and *Campylobacter* spp. using the BACTEC system. *J Microbiol Methods* 2021; 182: 106158.
- Matsuo T, Mori N, Mizuno A, Sakurai A, Kawai F, Starkey J, Ohkushi D, Abe K, Yamasaki M, Ito J, Yoshino K, Mikami Y, Uehara Y, Furukawa K. Infected aortic aneurysm caused by *Helicobacter cinaedi*: case series and systematic review of the literature. *BMC Infect Dis* 2020; 20: 854.
- Rasmussen SL, Ørsted I, Tarpgaard IH, Nielsen HL. *Helicobacter cinaedi* bacteraemia secondary to enterocolitis in an immunocompetent patient. *Gut Pathog* 2021; 13: 26.
- Hattori T, Nishiyama H, Ikegami S, Minoshima M, Kato H, Yuasa N. Clinical evaluation of FAPlus/FNPlus bottles compared with the combination of SA/SN and FA/FN bottles in the BacT/Alert blood culture system. *J Med Invest* 2020;67: 90-94.
- Peng W, Li H, Xu Y, Yan L, Tang Z, Hossein Mohseni A, Taghinezhad SS, Tang X, Fu X. Association of *Helicobacter bilis* Infection with the Development of Colorectal Cancer. *Nutr Cancer* 2020: 1-11. *Nutr Cancer* 2020; 1-11.
- Alvarez CS, Florio AA, Butt J, Rivera-Andrade A, Kroker-Lobos MF, Waterboer T, Camargo MC, Freedman ND, Graubard BI, Lazo M, Guallar E, Groopman JD, Ramirez-Zea M, McGlynn KA. Associations between *Helicobacter pylori* with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala. *Helicobacter* 2020; 25: e12756.

17. Segawa T, Ohno Y, Tsuchida S, Ushida K, Yoshioka M. *Helicobacter delphinicola* sp. nov., isolated from common bottlenose dolphins *Tursiops truncatus* with gastric diseases. *Dis Aquat Organ* 2020; 141: 157-169.
18. Shen Z, Mannion A, Lin M, Esmail M, Bakthavatchalu V, Yang S, Ho C, Feng Y, Smith B, Elliott J, Gresham V, VandeBerg JL, Samollow PB, Fox JG. *Helicobacter monodelphidis* sp. nov. and *Helicobacter didelphidarum* sp. nov., isolated from grey short-tailed opossums (*Monodelphis domestica*) with endemic cloacal prolapses. *Int J Syst Evol Microbiol* 2020; 70: 6032-6043.
19. Hu S, Jin D, Lu S, Liu S, Zhang J, Wang Y, Bai X, Xiong Y, Huang Y, Xu H, Wang Y, Du X, Ye C, Hänninen ML, Xu J. *Helicobacter himalayensis* sp. nov. isolated from gastric mucosa of *Marmota himalayana*. *Int J Syst Evol Microbiol* 2015; 65: 1719-1725.
20. Hu S, Niu L, Wu L, Zhu X, Cai Y, Jin D, Yan L, Zhao F. Genomic analysis of *Helicobacter himalayensis* sp. nov. isolated from *Marmota himalayana*. *BMC Genomics* 2020; 21: 826.
21. Marini RP, Patterson MM, Muthupalani S, Feng Y, Holcombe H, Swennes AG, Ducore R, Whary MM, Shen Z, Fox JG. *Helicobacter suis* and *Helicobacter pylori* infection in a colony of research macaques: characterization and clinical correlates. *J Med Microbiol* 2021; 70.
22. Cortez Nunes F, Letra Mateus T, Teixeira S, Barradas P, de Witte C, Haesebrouck F, Amorim I, Gärtner F. Presence of *Helicobacter pylori* and *H. suis* DNA in free-range wild boars. *Animals (Basel)* 2021; 11.
23. Richards-Rios P, Wigley P, López J, Wormell D, Barbón A. Changes in the faecal microbiome of pied tamarins (*Saguinus bicolor*) associated with chronic, recurrent diarrhoea and weight loss. *Anim Microbiome* 2021; 3: 1.
24. Lagerstedt E, Spillmann T, Airas N, Solano-Gallego L, Kilpinen S. Ménétrier-like disease in a Pointer with concurrent granulomatous gastritis, helicobacteriosis and leishmaniasis: a case report. *BMC Vet Res* 2021; 17: 98.
25. Ochoa S, Ojeda J, Martínez OA, Vidal-Veuthy B, Collado L. Exploring the role of healthy dogs as hosts of enterohepatic *Helicobacter* species using cultivation-dependent and -independent approaches. *Zoonoses Public Health* 2021; 68: 344-352.
26. Guerra Segundo DD, Mello CBE, Cargnelutti JF, Flores MM, Pedrotti LF, Antunes BN, Milech V, Velasquez OG, Martins LR, Pinto Filho STL. Evidence of *Helicobacter* spp. in saliva and gastric mucosa of domestic dogs in the central region of Rio Grande do Sul, Brazil. *Vet Med Int* 2021; 2021: 8857231.
27. Giarretta PR, Suchodolski JS, Jergens AE, Steiner JM, Lidbury JA, Cook AK, Hanifeh M, Spillmann T, Kilpinen S, Syrjä P, Rech RR. Bacterial biogeography of the colon in dogs with chronic inflammatory enteropathy. *Vet Pathol* 2020; 57: 258-265.
28. Matos R, De Witte C, Smet A, Berlamont H, De Bruyckere S, Amorim I, Gärtner F, Haesebrouck F. Antimicrobial susceptibility pattern of *Helicobacter heilmannii* and *Helicobacter ailurogastricus* isolates. *Microorganisms* 2020; 8.
29. Bierlein M, Hedgespeth BA, Azcarate-Peril MA, Stauffer SH, Gookin JL. Dysbiosis of fecal microbiota in cats with naturally occurring and experimentally induced *Tritrichomonas foetus* infection. *PLoS One*. 2021;16: e0246957.
30. Du W, Deng J, Yang Z, Zeng L, Yang X. Metagenomic analysis reveals linkages between cecal microbiota and feed efficiency in Xiayan chickens. *Poult Sci* 2020; 99: 7066-7075.
31. Hortelano I, Moreno Y, Moreno-Mesonero L, Ferrús MA. Deep-amplicon sequencing (DAS) analysis to determine the presence of pathogenic *Helicobacter* species in wastewater reused for irrigation. *Environ Pollut* 2020; 264: 114768.
32. Bali P, Lozano-Pope I, Pachow C, Obonyo M. Early detection of tumor cells in bone marrow and peripheral blood in a fast-progressing gastric cancer model. *Int J Oncol* 2021; 58: 388-396.
33. Bali P, Coker J, Lozano-Pope I, Zengler K, Obonyo M. Microbiome signatures in a fast- and slow-progressing gastric cancer murine model and their contribution to gastric carcinogenesis. *Microorganisms* 2021; 9.
34. Ji L, Qian W, Gui L, Ji Z, Yin P, Lin GN, Wang Y, Ma B, Gao WQ. Blockade of β -catenin-induced CCL28 suppresses gastric cancer progression via inhibition of Treg cell infiltration. *Cancer Res* 2020; 80: 2004-2016.
35. Kim W, Chu TH, Nienhüser H, Jiang Z, Del Portillo A, Remotti HE, White RA, Hayakawa Y, Tomita H, Fox JG, Drake CG, Wang TC. PD-1 Signaling promotes tumor-infiltrating myeloid-derived suppressor cells and gastric tumorigenesis in mice. *Gastroenterology* 2021; 160: 781-796.
36. Go DM, Lee SH, Lee SH, Woo SH, Kim K, Kim K, Park KS, Park JH, Ha SJ, Kim WH, Choi JH, Kim DY. Regulation of *Helicobacter*-induced gastritis by programmed death ligand 1-expressing classical dendritic cells. *Cell Mol Gastroenterol Hepatol* 2021; S2352-345X(21)00078-3.
37. Owyang SY, Zhang M, El-Zaatari M, Eaton KA, Bishu S, Hou G, Grasberger H, Kao JY. Dendritic cell-derived TGF- β mediates the induction of mucosal regulatory T-cell response to *Helicobacter* infection essential for maintenance of immune tolerance in mice. *Helicobacter* 2020; 25: e12763.
38. Chonwerawong M, Ferrand J, Chaudhry HM, Higgins C, Tran LS, Lim SS, Walker MM, Bhathal PS, Dev A, Moore GT, Sievert W, Jenkins BJ, D'Elios MM, Philpott DJ, Kufer TA, Ferrero RL. Innate immune molecule NLR5 protects mice from *Helicobacter*-induced formation of gastric lymphoid tissue. *Gastroenterology* 2020;159: 169-182.e8.
39. Balic JJ, Saad MI, Dawson R, West AJ, McLeod L, West AC, D'Costa K, Deswaerte V, Dev A, Sievert W, Gough DJ, Bhathal PS, Ferrero RL, Jenkins BJ. Constitutive STAT3 serine phosphorylation promotes *Helicobacter*-mediated gastric disease. *Am J Pathol* 2020; 190: 1256-1270.
40. Nienhüser H, Kim W, Malagola E, Ruan T, Valenti G, Middelhoff M, Bass A, Der CJ, Hayakawa Y, Wang TC. Mist1+ gastric isthmus stem cells are regulated by Wnt5a and expand in response to injury and inflammation in mice. *Gut* 2021; 70: 654-665.
41. Hu C, Liu W, Xu N, Huang A, Zhang Z, Fan M, Ruan G, Wang Y, Xi T, Xing Y. Silk fibroin hydrogel as mucosal vaccine carrier: induction of gastric CD4+TRM cells mediated by inflammatory response induces optimal immune protection against *Helicobacter felis*. *Emerg Microbes Infect* 2020; 9: 2289-22302.

42. Friedrich V, Forné I, Matzek D, Ring D, Popper B, Jochum L, Spriewald S, Straub T, Imhof A, Krug A, Stecher B, Brocker T. *Helicobacter hepaticus* is required for immune targeting of bacterial heat shock protein 60 and fatal colitis in mice. *Gut Microbes* 2021; 13: 1-20.
43. Han Q, Kono TJY, Knutson CG, Parry NM, Seiler CL, Fox JG, Tannenbaum SR, Tretyakova NY. Multi-Omics characterization of inflammatory bowel disease-induced hyperplasia/dysplasia in the Rag2^{-/-}/Il10^{-/-} mouse model. *Int J Mol Sci* 2020; 22: 364.
44. Ge Z, Ge L, Muthupalani S, Feng Y, Fox JG. Male-dependent promotion of colitis in 129 Rag2^{-/-} mice co-infected with *Helicobacter pylori* and *Helicobacter hepaticus*. *Int J Mol Sci* 2020; 21: 8886.
45. Seamons A, Haenisch M, Meeker S, Pershukina O, Brabb T, Treuting PM, Paik J. Protective Effects of ALDH1A Enzyme Inhibition on *Helicobacter*-Induced Colitis in Smad3^{-/-} Mice are Associated with Altered 4B7 Integrin Expression on Activated T Cells. *Nutrients* 2020; 12: 2927.
46. Alkarkoushi RR, Hui Y, Tavakoli AS, Singh U, Nagarkatti P, Nagarkatti M, Chatzistamou I, Bam M, Testerman TL. Immune and microRNA responses to *Helicobacter muridarum* infection and indole-3-carbinol during colitis. *World J Gastroenterol* 2020; 26: 4763-4785.
47. Xu Z, Liu W, Zhang Y, Zhang D, Qiu B, Wang X, Liu J, Liu L. Therapeutic and prebiotic effects of five different native starches on dextran sulfate sodium-induced mice model of colonic colitis. *Mol Nutr Food Res* 2021; 65: e2000922.
48. Ochoa S, Fernández F, Devotto L, France Iglesias A, Collado L. Virulence assessment of enterohepatic *Helicobacter* species carried by dogs using the wax moth larvae *Galleria mellonella* as infection model. *Helicobacter* 2021; e12808.
49. Altunöz D, Sayi Yazgan A. *Helicobacter*-stimulated IL-10-producing B cells suppress differentiation of lipopolysaccharide/*Helicobacter felis*-activated stimulatory dendritic cells. *Turk J Biol* 2021; 45: 214-224.
50. Azzi-Martin L, He W, Péré-Védrenne C, Korolik V, Alix C, Prochazkova-Carlotti M, Morel JL, Le Roux-Goglin E, Lehours P, Djavaheri-Mergny M, Grosset CF, Varon C, Dubus P, Ménard A. Cytotoxic distending toxin induces the formation of transient messenger-rich ribonucleoprotein nuclear invaginations in surviving cells. *PLoS Pathog* 2019; 15: e1007921.
51. He W, Azzi-Martin L, Velasco V, Lehours P, Dubus P, Djavaheri-Mergny M, Ménard A. The CDT of *Helicobacter hepaticus* induces pro-survival autophagy and nucleoplasmic reticulum formation concentrating the RNA binding proteins UNR/CSDE1 and P62/SQSTM1. *PLoS Pathog* 2021; 17: e1009320.
52. Zhu L, Zhu C, Cao S, Zhang Q. *Helicobacter hepaticus* induce colitis in male IL-10^{-/-} mice dependent by cytotoxic distending toxin B and via the activation of Jak/Stat signaling pathway. *Front Cell Infect Microbiol* 2021; 11: 616218.
53. Zhou G, Liang H, Gu Y, Ju C, He L, Guo P, Shao Z, Zhang J, Zhang M. Comparative genomics of *Helicobacter pullorum* from different countries. *Gut Pathog* 2020; 12: 56.